diprogenta ointment
organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin as sulfate - ointment - betamethasone as dipropionate 0.5 mg / 1 g; gentamicin as sulfate 1 mg / 1 g - topical treatment of dermatosis complicated by secondary infection caused by organisms sensitive to gentamicin
diprogenta cream
organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin (as sulfate) - cream - gentamicin (as sulfate) 1 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, combinations with antibiotics - for the relief of the inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.
hematopoietic progenitor cells, cord blood- human cord blood hematopoietic progenitor cell liquid
clinimmune labs, university of colorado blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 30 ml - hpc (hematopoietic progenitor cells), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. hpc, cord blood is contraindicated in patients with known hypersensitivity to dimethyl sulfoxide (dmso), dextran 40 or plasma proteins. [see description (11) and dosage and administration (2.2)] pregnancy category c. animal reproduction studies have not been conducted with hpc, cord
ascanex 50mg lyophilized powder for solution for infusion
progen pharmaceutical distributors; distributor: progen pharmaceutical distributors - caspofungin (as acetate) - lyophilized powder for solution for infusion - 50mg
anema 20mg/ml (100mg/5 ml) solution for injection (iv)
progen pharmaceutical distributors; distributor: corbridge group, inc. - iron sucrose - solution for injection (iv) - 20mg/ml (100mg/5 ml)
protitaz 4g/500 mg powder for injection iv
progen pharmaceutical distributors - piperacillin (as sodium) , tazobactam (as sodium) - powder for injection iv - 4g/500 mg
anastrozole progen
progen s.r.l., - anastrozole - film coated tablet - 1 milligram
anastrozole progen 1 milligram film coated tablet
progen s.r.l., - anastrozole - film coated tablet - 1 milligram
allocord- human cord blood hematopoietic progenitor cell injection, solution
ssm cardinal glennon children's medical center st. louis cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 35 ml - allocord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with allocord. it is also not known whether allocord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st
hemacord- human cord blood hematopoietic progenitor cell injection
new york blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - hemacord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with hemacord. it is also not known whether hemacord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st